The TRACTISS Protocol: A randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy in patients with primary Sjögren's Syndrome

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Brown, Sarah ^a   Navarro Coy, Nuria ^a,e   Pitzalis, Costantino ^b   Emery, Paul ^a,e   Pavitt, Sue ^a   Gray, Janine ^a   Hulme, Claire ^a   Hall, Frances ^c   Busch, Robert ^c,m   Smith, Pete ^d   Dawson, Luke ^d   Bombardieri, Michele ^b   Wan Fai, Ng ^f   Pease, Colin ^g   Price, Elizabeth ^h   Sutcliffe, Nurhan ⁱ   Woods, Clodagh ^g   Ruddock, Sharon ^a   Everett, Colin ^a   Reynolds, Catherine ^a   Skinner, Emma ⁿ   Poveda Gallego, Ana ^j   Rout, John ^j   Macleod, Iain ^k   Rauz, Saaeha ^l   Bowman, Simon ^o   more..

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^h GREAT WESTERN HOSPITAL   (United Kingdom)

ⁱ ROYAL LONDON HOSPITAL   (United Kingdom)

^j BIRMINGHAM DENTAL HOSPITAL   (United Kingdom)

^k NEWCASTLE DENTAL HOSPITAL   (United Kingdom)

^l UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^m UNIVERSITY OF ROEHAMPTON   (United Kingdom)

ⁿ KEELE UNIVERSITY   (United Kingdom)

^o QUEEN ELIZABETH HOSPITAL   (United Kingdom)

more..

Author keywords

Anti B cell; Double blind; Placebo; Rituximab; Sj gren's syndrome; Trial

Indexed keywords

BIOLOGICAL MARKER; PLACEBO; RITUXIMAB; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRY EYE; ECONOMIC EVALUATION; FATIGUE; FOLLOW UP; HUMAN; LACRIMATION; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PRIMARY SJOEGREN SYNDROME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SJOEGREN SYNDROME; TREATMENT DURATION; VERY ELDERLY; XEROSTOMIA; YOUNG ADULT; CLINICAL PROTOCOL; DISEASE DURATION; DRUG DOSE ESCALATION; FEMALE; GENE EXPRESSION; HEALTH CARE COST; MALE; T LYMPHOCYTE; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CLINICAL PROTOCOLS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; QUALITY OF LIFE; RESEARCH DESIGN; SALIVATION; SJOGREN'S SYNDROME; TEARS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896711661     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-21     Document Type: Article

References (18)

1. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Vitali C, Bombardieri S, Jonsson R, et al. Ann Rheum Dis 2002 61 554 558 10.1136/ard.61.6.554 12006334
2. Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR, UK Scand J Rheumatol 2004 33 39 43 10.1080/03009740310004676
3. Sjögren's syndrome: a community-based study of prevalence and impact. Thomas E, Hay EM, Hajeer A, Silman AJ, Br J Rheumatol 1998 37 1069 1076 10.1093/rheumatology/37.10.1069 9825745
4. UK Sjögren's interest group. Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool. Bowman SJ, Booth DA, Platts RG, Rheumatology 2004 43 758 764 10.1093/rheumatology/keh170 15039495
5. Safety and efficacy of Rituximab in Sjögren's syndrome: results of a randomised, placebo controlled trial. Dass S, Bowman SJ, Vital EM, et al. Ann Rheum Dis 2007 66 suppl 11 70 16877533
6. Rituximab treatment in primary Sjögren's syndrome: a double-blind placebo controlled trial. Meijer JM, Vissink A, Meiners PM, Spijkervet FKL, Kallenberg CGM, Bootsma H, ACR 2008 58 Suppl 1 713
7. Improvement of Sjögren's syndrome after two infusions of Rituximab (anti-CD20). Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Arthritis Care Res 2007 57 310 317 10.1002/art.22536
8. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Arthritis Rheum 2005 52 2740 2750 10.1002/art.21260 16142737
9. Tolerance and efficacy of Rituximab and changes in serum B-cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Seror R, Sordet C, Guillevin L, et al. Ann Rheum Dis 2007 66 351 357 10.1136/ard.2006.057919 16950808
10. Longitudinal analysis of lymphocyte subsets in patients with primary Sjögren's syndrome (PSS) treated with hRituximab. Results from an open-label clinical trial. Levesque MC, et al. Arthritis Rheum 2007 56 9 445
11. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of Rituximab-treated patients with Sjögren's syndrome. Pers JO, et al. Arthritis Rheum 2007 56 1464 1477 10.1002/art.22603 17469105
12. Increase of B-cell-activating factor of the TNF family (BAFF) after Rituximab treatment: insights into a new regulating system of BAFF production. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X, Ann Rheum Dis 2007 66 700 703 10.1136/ard.2006.060772 17040963
13. Tolerance and efficacy of rituximab in primary Sjögren syndrome: final results of a randomised controlled trial [abstract]. Devauchelle Pensec V, Mariette X, Jousse Joulin S, Berthelot JM, Perdriger A, Hachulla E, et al. Arthritis Rheum 2012 64 1079
14. United Kingdom Primary Sjögren's Syndrome Registry-a united effort to tackle an orphan rheumatic disease. Ng WF, Bowman SJ, Griffiths B, Rheumatology 2011 50 32 39 10.1093/rheumatology/keq240 20693261
15. Direct healthcare costs and predictors of costs in patients with primary Sjögren's syndrome. Callaghan R, et al. Rheumatology 2007 46 105 111 10.1093/rheumatology/kel155 16728437
16. White blood cell counts in healthy Jamaican adults. Urquhart NE, Capildeo KD, Sargeant LA, Wharfe G, Hisada M, Hanchard B, West Indian Med J 2008 57 2 147 151 19565958
17. EuroQoL Health related quality of life measurement. Results of the Swedish questionnaire exercise. Brooks RG, et al. Health Policy 1991 18 1 37 48 10.1016/0168-8510(91)90142-K 10112300
18. The effect of past and present illness experience on the valuation of healthstates. Kind P, Dolan P, Med Care 1995 33 4 Suppl S255 263 7723454